Jillian Mullin

Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia

Courtney D. DiNardo, Wei‐Ying Jen, Koichi Takahashi et al. · Leukemia · 2025 · 35 citations · Full text

Medicine, Hematology, Oncology +16

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML

Courtney D. DiNardo, Jennifer Marvin‐Peek, Sanam Loghavi et al. · Journal of Clinical Oncology · 2025 · 21 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update

Himachandana Atluri, Jillian Mullin, Koichi Takahashi et al. · Blood · 2023 · 18 citations

Medicine, Pharmacology, Pharmacotherapy +6

FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML.

Wei‐Ying Jen, Koichi Takahashi, Sanam Loghavi et al. · Journal of Clinical Oncology · 2024 · 18 citations

Medicine, Oncology, Pharmacology +15